Merck KGaA Stock

Price

Target price

/ Tradegate WKN: 659990 / Symbol: MKGAF / Name: Merck / Stock / Pharmaceuticals / Large Cap /

Please give a prediction to see the opinions of the community

sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Your prediction

Merck KGaA Stock

With only a change of €0.10 (0.060%) the Merck KGaA price is nearly unchanged from yesterday.

Our community is currently high on Merck KGaA with 4 Buy predictions and 0 Sell predictions.

As a result the target price of 190 € shows a positive potential of 21.91% compared to the current price of 155.85 € for Merck KGaA.

For the coming years our community has positive and negative things to say abot the Merck KGaA stock. Criterium "Return on equity" gathered the most positive votes but regarding "Expected dividend yield" there were negative voices in the community.

What does Merck do?

Pros and Cons of Merck KGaA in the next few years

Pros

C******** o* t** e**********

S********** s********

G***** c******* t* c**********

Cons

W********* I********* f** t** n*** y****

M***** P*******

B****

Tell us your opinion to access the 'Wisdom of the Crowds'

Your Opinion

Legal notice

Performance of Merck KGaA vs. its peers

Security	Change(%)	1w	1m	1y	YTD	3y	5y
Merck KGaA
Bayer AG
Biogen Inc.
Pfizer Inc.

more about Merck KGaA

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.

It appears that Merck, operating under the US symbol MKGAF, showcases stable financial performance within the pharmaceuticals industry. The company has shown consistent growth in total assets and net income in recent years, and its overall financial position and liquidity seem to be in good shape.

In conclusion, Merck's financials reveal a generally positive situation for the company, with growth in total assets, net income, and operating cash flows. However, certain areas, such as increased long-term debt, negative net tangible assets, and changes in net working capital necessitate careful monitoring. As an analyst, monitoring Merck's financial performance and management strategies will be crucial to ensure sustained growth and stability in the coming years.

Feedback